1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
CellSeed Inc.

CellSeed Inc.

TTSE:7776
192.00
JPY
-8.00
(-4.00%)
8.49BMarket Cap
Nov 13Next Earn
CellSeed Inc.
TSE:7776
(Tokyo Stock Exchange)

Recent

price

192.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
13.33
16.13
13.31
14.79
10
22.21
11.03
8.21
89.78
23.48
14.07
9.4
6.04
6.61
5.78
2.41
- -
Revenue per Share
-200.98
-270.07
-161.79
-81.76
-67.5
-61.56
-154.95
-93.3
11.35
-66.6
-55.31
-53.08
-36.31
-29.43
-25.72
-31.82
- -
Basic EPS, GAAP
-231.11
-241.41
-138.05
-69.86
-70.76
-105.9
-131
-72.61
-26.96
-50.31
-50.16
-52.81
-35.06
-27.85
-26.46
-29.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
358.34
98.12
15.78
310.46
324.8
268.98
126.37
110.17
123.2
103.67
95.35
58.82
48.25
68.81
62.4
35.67
45.12
Book Value per Share
356.83
98.12
15.78
310.46
324.8
268.98
126.37
110.11
123.15
103.63
95.35
58.82
48.25
68.81
62.4
35.67
45.12
Tangible Book Value per Share
5
5
6
7
9
9
9
10
11
12
14
17
21
29
33
35
36
Basic Weighted Avg Shares
67
86
75
106
86
193
101
85
1,026
276
199
162
126
190
193
84
- -
Sales/Revenue/Turnover
-879.49
-974.47
-568.8
-166.46
-244.78
-78.84
-1,404.42
-1,124.85
13.65
-283.08
-360.72
-534.48
-587.86
-366.99
-437.91
-1,250.18
- -
Operating Margin (%)
18
21
6
1
3
9
8
5
5
5
10
2
8
8
- -
- -
- -
Depreciation Expense
-1,010
-1,442
-913
-585
-583
-535
-1,414
-966
130
-782
-784
-913
-760
-847
-860
-1,104
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
7.77
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,507.58
-1,674.56
-1,215.22
-552.7
-675.01
-277.16
-1,404.8
-1,136.21
12.64
-283.66
-392.98
-564.64
-600.88
-445.23
-444.87
-1,319.46
- -
Profit Margin (%)
1,814
525
70
2,499
2,785
2,084
1,083
1,174
1,331
1,135
1,502
836
1,051
2,228
2,209
1,273
1,764
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
160
159
151
144
133
105
89
LT Debt
1,908
534
95
2,536
2,817
2,390
1,164
1,259
1,412
1,346
1,526
1,045
1,178
2,165
2,163
1,268
1,774
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
9.54
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
9.72
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-72.84
-118.09
-290.31
-44.44
-21.77
-20.56
-79.58
-79.77
9.72
-56.75
-54.58
-71.01
-68.35
-50.64
-39.73
-64.35
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
8
- -
28
LT Borrowings
139
- -
89
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
39
39
Market Capitalization
11,840
11,351
8,493

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
2,306
- -
1,952
Cash, Cash Equivalents & STI
2,174
- -
1,792
Accounts Receivable, Net
27
- -
11
Inventories
49
- -
91
Total Current Liabilities
137
- -
188
Payables & Accruals
- -
- -
- -
ST Debt
8
- -
28
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.12%
4.7%
-41.37%
Free Cash Flow
8.88%
8.59%
14.84%
Net Income, GAAP
-64.26%
8.22%
28.41%
Sales/Revenue/Turnover
89.67%
-9.08%
-56.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34
42
- -
- -
193
2025
- -
- -
- -
- -
84
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.24
-7.5
- -
- -
-25.72
2025
- -
- -
- -
- -
-31.82
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
CellSeed Inc. CellSeed Inc. (7776.T) engages primarily in the research, development, commercialization, and sale of cell sheet regenerative medicines and related support products. The company offers epithelial cell sheets for esophageal and corneal regeneration, regenerated cartilage sheets, chondrocyte sheets for knee osteoarthritis treatment, and cardiac patches for heart disease; it also provides intelligent cell cultureware including UpCell temperature-responsive dishes for cell-sheet engineering, RepCell for cell collection, HydroCell low cell binding cultureware, ThermoPlate III heating elements, and cellZscope automated monitoring systems, alongside contract development and manufacturing services for cell products through its in-house cell processing facility. Founded in May 2001 and headquartered at 15F East Wing, Telecom Center Building, 2-5-10 Aomi, Koto-ku, Tokyo, Japan, CellSeed Inc. operates in the biotechnology sector with a focus on regenerative medicine, serving clinical trials, research institutions, and global markets primarily in Japan and internationally through sales of cultureware since 2008. In recent developments, the company commenced Phase 3 clinical trials for its esophageal epithelial cell sheet following Sakigake Designation in 2017, is preparing a Phase 3 submission for allogeneic chondrocyte cell sheets, established Up Cell Biomedical Inc. in Taiwan in 2020 as a subsidiary, launched the Aomi Cell Cultureware Innovation Center in 2021 for new equipment development, transitioned to a Company with an Audit and Supervisory Committee in 2021, moved to the Tokyo Stock Exchange Growth Market in 2022 amid exchange reorganization, and cancelled its business alliance with Taiwan's MetaTech(AP) Inc. in December 2023.